SPP-002
Based on 1 Customer Validation
SPP-002 is a ST6GAL1 inhibitor with a human IC50 of 16.7 μM. SPP-002 selectively inhibits N-glycan sialylation over O-glycan sialylation and binds strongly to the enzyme active site. SPP-002 suppresses expression of signaling proteins in the integrin/FAK/paxillin pathway. SPP-002 can be used for the research of triple negative breast cancer metastasis.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 98.0%
- CAS. Nr.: 3067911-81-0
- Formel: C24H41KO5S
- Molecular Weight:480.74
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Metabolic Enzyme Compound Library
HY-L146
-
Highly Selective Inhibitors Library
HY-L158
-
Mitophagy Compound Library
HY-L180
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Biologische Aktivität
|
ST6Gal 16.7 nM (IC50) |
SPP-002 (Compound 2) (50-1000 μM) potently and selectively inhibits human ST6GAL1 with an IC50 of 16.7 μM, while exhibiting minimal activity against rat ST3GAL1 (IC50 > 1000 μM)[1].
SPP-002 (0.5-80 μM) is non-cytotoxic to MDA-MB-231 human triple-negative breast cancer cells at concentrations up to 80 μM[1].
SPP-002 (60 μM; 16 h) inhibits the migration of MDA-MB-231 human triple-negative breast cancer cells in vitro[1].
SPP-002 (60 μM) potently inhibits the invasion of MDA-MB-231 human triple-negative breast cancer cells in vitro, with a more pronounced effect on invasion than migration[1].
SPP-002 (60 μM; 24-48 h) moderately reduces the adhesion of MDA-MB-231 human triple-negative breast cancer cells to collagen IV and fibronectin in vitro, with greater activity than lithocholic acid[1].
SPP-002 (20-80 μM; 48 h) suppresses sialylation of integrin subunits (αv, α5, β1, β3, β4, β5) in MDA-MB-231 human triple-negative breast cancer cells in vitro in a dose-dependent manner[1].
SPP-002 (20-80 μM; 1-18 h) inhibits phosphorylation of FAK and paxillin in MDA-MB-231 human triple-negative breast cancer cells in both time-dependent and dose-dependent manners, while not altering total FAK or paxillin protein levels[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-231 human triple-negative breast cancer cells
-
Concentration:60 μM
-
Incubation Time:16 h
-
Result:Decreased the migration potential of MDA-MB-231 cells relative to untreated control cells and cells treated with other test compounds.
The anti-migration activity was attributed to ST inhibitory effects rather than inherent cytotoxicity.
-
Cell Line:MDA-MB-231 human triple-negative breast cancer cells
-
Concentration:20 μM; 40 μM; 80 μM
-
Incubation Time:48 h
-
Result:Dose-dependently suppressed the sialylation of integrin αv, α5, β1, β3, β4, and β5 subunits.
-
Cell Line:MDA-MB-231 human triple-negative breast cancer cells
-
Concentration:20 μM; 40 μM; 80 μM
-
Incubation Time:1 h; 2 h; 4 h; 6 h; 8 h; 18 h
-
Result:Time-dependently suppressed phosphorylation of FAK (Y397, Y576/577) and paxillin (Y118) starting at 2 h post-treatment, with no significant change in total FAK and paxillin protein levels.
Dose-dependently suppressed phosphorylation of FAK (Y397, Y576/577) and paxillin (Y118) after 2 h of treatment, with minimal change in total FAK and paxillin expression.
Chemical Information
-
CAS. Nr. 3067911-81-0
-
Appearance Solid
-
Molecular Weight 480.74
-
Formel C24H41KO5S
-
Color White to off-white
-
SMILES
C[C@H](CCCOS(=O)(O[K])=O)[C@H]1CC[C@@]2([H])[C@]3([H])CC[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
DMSO : ≥ 25 mg/mL (52.00 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.20 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.20 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (277 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0801 mL | 10.4006 mL | 20.8013 mL | 52.0032 mL |
| 5 mM | 0.4160 mL | 2.0801 mL | 4.1603 mL | 10.4006 mL | |
| 10 mM | 0.2080 mL | 1.0401 mL | 2.0801 mL | 5.2003 mL | |
| 15 mM | 0.1387 mL | 0.6934 mL | 1.3868 mL | 3.4669 mL | |
| 20 mM | 0.1040 mL | 0.5200 mL | 1.0401 mL | 2.6002 mL | |
| 25 mM | 0.0832 mL | 0.4160 mL | 0.8321 mL | 2.0801 mL | |
| 30 mM | 0.0693 mL | 0.3467 mL | 0.6934 mL | 1.7334 mL | |
| 40 mM | 0.0520 mL | 0.2600 mL | 0.5200 mL | 1.3001 mL | |
| 50 mM | 0.0416 mL | 0.2080 mL | 0.4160 mL | 1.0401 mL |
SPP-002 Related Classifications
HY-163548 Related Classifications
Powered by Bioz